MCA logo



FDA Approves Omisirge Cell Therapy to Reduce Infection Risk in Patients with Hematologic Malignancies

Omisirge is used in adults and children aged 12+ for cord blood transplant after myeloablative conditioning in hematologic malignancies.

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

Robert Downery Jr, Bipolar
World Bipolar Day: 5 Famous Examples of Success with the Condition

This article explores World Bipolar Day and highlights five famous individuals who have found success despite their bipolar condition. The article also discusses the higher prevalence of bipolar disorder in Asian populations and presents research findings on the racial/ethnic differences in bipolar subtype prevalence.

Read More »